Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
Public ClinicalTrials.gov record NCT02477332. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a placebo and active-controlled phase 2b dose-finding study to evaluate efficacy and safety of QGE031 monthly subcutaneous injections as add-on therapy in patients with Chronic Spontaneous Urticaria.
Study identification
- NCT ID
- NCT02477332
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 382 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 14, 2015
- Primary completion
- Nov 1, 2016
- Completion
- Jun 11, 2017
- Last update posted
- Jan 4, 2021
2015 – 2017
United States locations
- U.S. sites
- 25
- U.S. states
- 18
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Birmingham | Alabama | 35209 | — |
| Novartis Investigative Site | Scottsdale | Arizona | 85251 | — |
| Novartis Investigative Site | Little Rock | Arkansas | 72205 | — |
| Novartis Investigative Site | Huntington Beach | California | 92647 | — |
| Novartis Investigative Site | Mission Viejo | California | 92691 | — |
| Novartis Investigative Site | Sarasota | Florida | 34233 | — |
| Novartis Investigative Site | Evansville | Indiana | 47713 | — |
| Novartis Investigative Site | Louisville | Kentucky | 40291 | — |
| Novartis Investigative Site | Owensboro | Kentucky | 42301 | — |
| Novartis Investigative Site | Waldorf | Maryland | 20602 | — |
| Novartis Investigative Site | Minneapolis | Minnesota | 55402 | — |
| Novartis Investigative Site | Rochester | Minnesota | 55905 | — |
| Novartis Investigative Site | St Louis | Missouri | 63141 | — |
| Novartis Investigative Site | Forest Hills | New York | 11375 | — |
| Novartis Investigative Site | The Bronx | New York | 10461 | — |
| Novartis Investigative Site | Asheville | North Carolina | 28801 | — |
| Novartis Investigative Site | Cincinnati | Ohio | 45231 | — |
| Novartis Investigative Site | Toledo | Ohio | 43617 | — |
| Novartis Investigative Site | Lake Oswego | Oregon | 97035 | — |
| Novartis Investigative Site | Providence | Rhode Island | 02906 | — |
| Novartis Investigative Site | Dallas | Texas | 75230 | — |
| Novartis Investigative Site | Fort Worth | Texas | 76132 | — |
| Novartis Investigative Site | Katy | Texas | 77450 | — |
| Novartis Investigative Site | South Burlington | Vermont | 05403 | — |
| Novartis Investigative Site | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 57 non-U.S. sites.
Recently updated Chronic Spontaneous Urticaria trials
Other public records listing Chronic Spontaneous Urticaria. Sorted by last update posted; newest first. Not a recommendation.
- NCT07408219: A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients Recruiting
- NCT06873516: Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU) Active, not recruiting
- NCT05677451: 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up Recruiting
- NCT07256392: Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria Recruiting
- NCT07540910: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults Recruiting
- NCT07358364: Remibrutinib in Real-world Clinical Practice Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02477332, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 4, 2021 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02477332 live on ClinicalTrials.gov.